Scientist, Invivo Pharmacology

Job description

***Let’s build the future of medicine—together.*** Scientist, In Vivo Pharmacology Hyderabad, India | Full-Time **YOUR ROLE**As a Scientist, In Vivo Pharmacology at Enveda, you will be an innovative, self-motivated member of our in vivo pharmacology team — establishing and validating in vivo models, evaluating test compounds across disease areas, and generating the translational data that drives our drug discovery pipeline. Reporting to the Principal Scientist, Biology, your work will directly accelerate the progression of novel therapeutics toward patients. **WHAT YOU'LL DO** - Execute in vivo pharmacology studies to evaluate small molecule drug candidates, investigate mechanisms of action, and explore novel therapeutic hypotheses - Contribute to study design and execution of PK, PD, and efficacy studies from early exploration through IND stage - Perform standard mouse procedures: plasma/serum collection, IP/IV injections, necropsies, and tissue collection per established protocols - Record experimental data accurately and on time in company-specified formats; contribute to study protocols and SOPs - Participate in cross-functional team activities and contribute creative ideas to advance research projects ### WHAT WE'RE LOOKING FOR - M.Pharm. with 5-7 years, or PhD with 0-2 years, of experience in the drug discovery industry - Proficient in standard in vivo techniques: animal handling, blood collection, dosing, rodent survival surgery, necropsy, and tissue dissection - Familiar with animal ethics and regulatory compliance requirements - Self-motivated, proactive, and able to work independently and collaboratively - Strong scientific curiosity, work ethic, and excellent oral and written communication skills We hire for trajectory, not just credentials. If you meet most of the above and care deeply about this problem, we want to hear from you. ### ABOUT ENVEDA We're a clinical-stage, AI-enabled biotech discovering medicines four times faster than the industry standard. We recently raised $150M in a Series D, reached unicorn status, and advanced our first drug into Phase 2 trials. Forbes named us one of *America's Best Startup Employers*. Newsweek recognized us as a *Top 100 Most Loved Workplace*. We're building something rare and we're just getting started.